Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.299,71 +25,66 (+0,07%) EUR/USD
1,0719 +0,0001 (+0,01%) Bitcoin EUR
53.551,99 -2.383,60 (-4,26%) CMC Crypto 200
1.259,79 -79,28 (-5,92%)
Immunocore Holdings plc (6YG.MU)
| Chiusura precedente | 54,00 |
| Aperto | 53,50 |
| Denaro | 55,00 x N/D |
| Lettera | 55,50 x N/D |
| Min-Max giorno | 53,50 - 53,50 |
| Intervallo di 52 settimane | 40,40 - 69,00 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | 2,675B |
| Beta (5 anni mensile) | 0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,32 |
| Prossima data utili | 08 mag 2024 - 12 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireImmunocore announces upcoming presentation and posters at ESMO 2023
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 07 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed
- GlobeNewswire
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor co
- GlobeNewswire
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024 Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expans
